Formulation Strategies and Advances in Sustained Release Tablets for Rheumatoid Arthritis Therapy: A Comprehensive Review

Abstract

An autoimmune disease that affects the entire body, rheumatoid arthritis (RA) is characterized by increasing joint inflammation, discomfort, and disability. Long-term medication is still the mainstay of managing RA, with corticosteroids, disease-modifying antirheumatic medications (DMARDs), and non-steroidal anti-inflammatory medicines (NSAIDs) all being essential for symptom management. However, the frequent dosing required by traditional immediate-release oral dose forms frequently results in poor patient compliance, variable plasma drug concentrations, and a higher risk of severe systemic and gastrointestinal effects. Formulations for sustained release (SR) tablets have been a successful way to get around these restrictions by preserving therapeutic drug levels for longer stretches of time, reducing the frequency of doses, and enhancing patient compliance. Only the formulation characteristics of sustained release tablets created to treat rheumatoid arthritis are included in this review. Sustained release therapy's justification, physicochemical and biopharmaceutical factors, formulation strategies, polymers used, release mechanisms, assessment criteria, and new developments in sustained release tablet technology are all covered. For sustained release formulations to guarantee consistent performance, superior therapeutic results, and improved safety profiles, additional focus is spent on optimizing drug release kinetics, choosing appropriate excipients, manufacturing processes, and quality control procedures.

Keywords

Introduction

Rheumatoid arthritis (RA) is a chronic and progressive inflammatory disorder characterized by persistent synovial inflammation, which ultimately leads to joint deformities, cartilage destruction, and bone erosion [1]. In addition to joint damage, RA is considered a systemic condition that may involve extra-articular complications affecting the musculoskeletal, respiratory, and cardiovascular systems. Epidemiological studies indicate that RA affects approximately 0.5–1% of the global population, with a higher prevalence observed in females compared to males [2]. Due to its chronic inflammatory nature, patients commonly experience pain, morning stiffness, reduced functional capacity, and a significant decline in overall quality of life, making long-term pharmacological management essential.

The primary objectives of RA therapy include reducing inflammation, relieving pain, preventing structural joint damage, and improving patient mobility and functional outcomes. Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed during the early stages of RA for symptomatic relief, either as monotherapy or alongside disease-modifying antirheumatic drugs (DMARDs) [3]. However, many NSAIDs possess relatively short biological half-lives and are commonly available as immediate-release formulations, which require frequent administration to maintain therapeutic drug levels [4]. Such dosing schedules often result in fluctuations in plasma drug concentration, potentially leading to inconsistent symptom control and an increased risk of dose-related adverse effects such as gastrointestinal irritation, ulceration, and bleeding [5]. Moreover, repeated daily dosing may negatively impact patient adherence, which is a major concern in chronic diseases like RA.

Oral drug delivery remains the preferred route for RA treatment due to its convenience, cost-effectiveness, and high level of patient acceptance [3]. To overcome the limitations associated with immediate-release dosage forms, sustained release (SR) tablet formulations have gained considerable attention. These formulations are designed to release the drug at a controlled and predetermined rate over an extended period, thereby maintaining more stable plasma drug concentrations and reducing dosing frequency [4]. By minimizing peak–trough fluctuations, sustained release systems may decrease adverse effects and enhance patient compliance with long-term therapy. Therefore, sustained release tablets represent a promising pharmaceutical approach for improving the management of rheumatoid arthritis.

This review primarily focuses on formulation-based strategies for sustained release tablets in RA therapy, emphasizing pharmaceutical design, polymer selection, and drug release mechanisms rather than clinical outcome evaluation.

2. Rationale for Sustained Release Tablets in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that requires continuous, long-term pharmacological therapy to control pain, inflammation, and disease progression. Conventional immediate-release (IR) oral dosage forms often produce rapid drug absorption followed by a sharp decline in plasma drug concentration, which may quickly fall below the therapeutic range [2]. Such pharmacokinetic fluctuations necessitate frequent dosing to maintain clinical efficacy, posing significant challenges in the long-term management of chronic conditions like RA.

2.1 Limitations of Immediate-Release Dosage Forms

Many drugs used in RA management, particularly non-steroidal anti-inflammatory drugs (NSAIDs), possess relatively short biological half-lives and are rapidly eliminated from systemic circulation [6]. Frequent administration of IR formulations leads to pronounced peak–trough variations in plasma drug levels, resulting in inconsistent therapeutic outcomes. High peak concentrations are often associated with dose-dependent adverse effects, especially gastrointestinal irritation, ulcer formation, and bleeding, while low trough levels may contribute to inadequate symptom control [7]. Additionally, complex dosing regimens negatively affect patient adherence, which is a critical factor influencing long-term treatment success in chronic diseases such as RA.

2.2 Advantages of Sustained Release Tablet Formulations

Sustained release (SR) tablets are designed to deliver the drug at a controlled and predetermined rate over an extended duration, thereby maintaining relatively stable plasma concentrations within the therapeutic window [4]. One of the major advantages of SR systems in RA therapy is the ability to maintain steady-state drug levels, minimizing peak-related toxicity and preventing subtherapeutic fluctuations. Reduced dosing frequency, often allowing once-daily administration, enhances patient convenience and improves treatment adherence [5]. From a formulation perspective, SR tablets also reduce pill burden and improve overall therapy acceptance, particularly among elderly patients who are commonly prescribed multiple medications. Controlled drug release ensures prolonged analgesic and anti-inflammatory effects, which is essential for effective management of chronic joint pain and stiffness associated with RA [8].

2.3 Suitability of RA Drugs for Sustained Release Systems

Several drugs used in RA therapy are well suited for sustained release formulations based on their pharmacokinetic and physicochemical properties. NSAIDs such as diclofenac sodium, ibuprofen, indomethacin, and ketoprofen typically exhibit short elimination half-lives in conventional formulations, requiring multiple daily doses. Their good gastrointestinal absorption and dose-related side effects make them appropriate candidates for controlled-release delivery systems [8].

Sustained release formulations help address challenges related to rapid drug clearance and fluctuating bioavailability by prolonging gastrointestinal residence time and enabling gradual drug release. The use of polymeric matrices and release-modifying excipients allows precise modulation of drug release kinetics, thereby improving both safety and therapeutic performance.

2.4 Formulation Perspective

From a pharmaceutical formulation standpoint, sustained release tablets provide an effective strategy for optimizing the pharmacokinetic behaviour of RA medications. By incorporating suitable polymers and matrix systems, SR formulations overcome limitations associated with short drug half-lives, frequent dosing, and adverse effects. Consequently, sustained release tablet systems play a significant role in improving long-term therapeutic management of rheumatoid arthritis [4].

3. Drug Candidates for Sustained Release Tablet Formulation in Rheumatoid Arthritis

The selection of suitable drug candidates plays a critical role in the successful development of sustained release (SR) tablet formulations. Not all drugs are appropriate for sustained release delivery; therefore, careful evaluation of physicochemical properties, pharmacokinetic behaviour, and biological characteristics is essential. In the context of rheumatoid arthritis (RA), sustained release formulations are particularly beneficial for drugs that require long-term administration and possess relatively short biological half-lives. Among the various therapeutic classes used in RA management, non-steroidal anti-inflammatory drugs (NSAIDs) and certain corticosteroids have been widely investigated for sustained release tablet development.

3.1 Desired Drug Properties for Sustained Release Formulation

An ideal candidate for sustained release tablet formulation generally exhibits a short to moderate elimination half-life, typically ranging between two and eight hours. Drugs with such half-lives often require frequent dosing in conventional immediate-release formulations, making them suitable for sustained release systems designed to prolong therapeutic activity and reduce dosing frequency [5]. Additionally, drugs with sufficient potency are preferred, as sustained release tablets are limited by tablet size and drug loading capacity. Appropriate aqueous solubility is another important factor in sustained release formulation. Highly water-soluble drugs may lead to rapid drug release or dose dumping if not adequately controlled by suitable polymers, whereas poorly soluble drugs may demonstrate inconsistent or incomplete release profiles [8]. Therefore, drugs with moderate solubility are generally considered optimal for achieving controlled and predictable release behaviour.

For oral sustained release systems, drug absorption throughout the gastrointestinal tract is also essential. Drugs with narrow absorption windows restricted to the upper gastrointestinal region may exhibit reduced bioavailability when formulated as sustained release products. Moreover, the drug should maintain chemical and physical stability across varying gastrointestinal pH conditions to ensure consistent release and absorption [3].

3.2 Common Drugs Used in Sustained Release Tablets for RA

Several NSAIDs commonly prescribed in RA therapy meet the criteria for sustained release formulation. Diclofenac sodium is one of the most extensively studied candidates due to its short half-life, strong anti-inflammatory activity, and favourable gastrointestinal absorption characteristics [9]. Sustained release formulations of diclofenac have demonstrated improved patient adherence and reduced incidence of gastrointestinal side effects.

Ibuprofen is another widely used NSAID suitable for sustained release delivery systems, primarily because of its relatively short biological half-life. Controlled-release ibuprofen formulations help maintain steady plasma concentrations while minimizing peak-related adverse effects [10].

Indomethacin and ketoprofen, both potent NSAIDs, require frequent administration in immediate-release form due to their pharmacokinetic profiles. Their good gastrointestinal absorption and therapeutic effectiveness make them suitable candidates for sustained release matrix tablet systems [11]. Although naproxen possesses a comparatively longer half-life than many other NSAIDs, sustained release formulations have been developed to further enhance therapeutic consistency and reduce dosing frequency in chronic RA management.

Overall, these drugs have been extensively explored in sustained release tablet development due to their established clinical efficacy in RA treatment and favourable pharmacokinetic characteristics, making them well suited for controlled drug delivery approaches.

4. Methods for Formulating Sustained Release Tablets

The development of sustained release (SR) tablets for rheumatoid arthritis (RA) requires the selection of appropriate formulation strategies capable of delivering the drug at a controlled rate over an extended period. The choice of formulation method depends on several factors, including the physicochemical properties of the drug, desired release profile, dose requirements, stability considerations, and manufacturing feasibility. Among the various approaches, matrix systems, reservoir systems, and multiparticulate systems compressed into tablets are widely used in the design of sustained release formulations for RA therapy [8].

4.1 Matrix Tablet Systems

Matrix tablet systems represent one of the most commonly used sustained release approaches due to their simplicity, cost-effectiveness, and ease of large-scale manufacturing. In these systems, the active pharmaceutical ingredient is uniformly dispersed within a polymeric matrix that acts as a release-controlling barrier. Upon contact with gastrointestinal fluids, the matrix regulates drug release through mechanisms such as diffusion, swelling, and gradual erosion [4]. Matrix tablets are particularly suitable for NSAIDs and other RA medications that require prolonged therapeutic action and relatively stable plasma drug levels.

4.1.1 Hydrophilic Matrix Systems

Hydrophilic matrix systems utilize polymers that swell upon hydration, forming a gel layer around the tablet surface. Commonly used hydrophilic polymers include hydroxypropyl methylcellulose (HPMC), sodium alginate, xanthan gum, guar gum, and sodium carboxymethyl cellulose [12]. When exposed to gastrointestinal fluids, these polymers hydrate rapidly and form a viscous gel barrier that controls both water penetration and drug diffusion.

Drug release from hydrophilic matrices generally occurs through diffusion across the gel layer along with gradual polymer relaxation or erosion. Among available polymers, HPMC has been extensively investigated because of its safety profile, reproducibility, and ability to provide predictable and controlled release characteristics [13].

4.1.2 Hydrophobic Matrix Systems

Hydrophobic matrix systems employ water-insoluble or lipid-based polymers to slow down fluid penetration into the tablet matrix, thereby prolonging drug release. Examples of commonly used hydrophobic materials include ethyl cellulose, hydrogenated castor oil, glyceryl behenate, and stearic acid [14]. In such systems, drug release primarily occurs through diffusion via pores or channels formed within the matrix structure.

Hydrophobic matrices are particularly useful for highly water-soluble drugs, where hydrophilic systems alone may lead to rapid release or dose dumping. Compared with hydrophilic matrices, hydrophobic systems often provide slower matrix degradation and more consistent release profiles. In many formulations, a combination of hydrophilic and hydrophobic polymers is employed to achieve optimized drug release behaviour in sustained release tablets for RA [9].

4.2 Reservoir Systems

Reservoir systems consist of a drug-containing core surrounded by a polymeric coating that regulates drug release. The release rate is primarily influenced by the thickness, composition, and permeability of the coating membrane. Polymers such as ethyl cellulose, polyvinyl acetate, and methacrylate copolymers (e.g., Eudragit) are commonly used in reservoir-based formulations [15].

These systems allow precise control over drug release kinetics and are suitable for drugs requiring well-defined release profiles in RA therapy. However, manufacturing complexity and the risk of dose dumping in cases of coating failure remain important considerations. Despite these challenges, reservoir systems have demonstrated the potential to improve therapeutic consistency while reducing dosing frequency [5].

4.3 Multiparticulate Systems Compressed into Tablets

Multiparticulate sustained release systems involve the incorporation of drug-loaded pellets or granules with controlled-release properties into a tablet dosage form. These pellets are typically produced using techniques such as layering or extrusion–spheronization before compression into tablets [18]. Compared with single-unit systems, multiparticulate formulations offer advantages including improved dose uniformity, reduced inter- and intra-patient variability, and a lower risk of dose dumping.

In RA management, multiparticulate sustained release tablets provide more uniform drug release patterns and enhanced gastrointestinal distribution, contributing to improved safety and therapeutic effectiveness. These systems are particularly beneficial for high-dose NSAIDs and drugs associated with gastrointestinal irritation [16].

5. Polymers Used in Sustained Release Tablets for Rheumatoid Arthritis

Polymers play a fundamental role in the design and performance of sustained release (SR) tablets, as they regulate drug release rate, maintain matrix integrity, and ensure overall formulation stability. The selection of an appropriate polymer system is a critical formulation decision because it directly influences swelling behaviour, drug diffusion, erosion patterns, and overall release kinetics. Both synthetic and natural polymers have been extensively investigated in sustained release formulations developed for rheumatoid arthritis (RA) due to their distinct physicochemical properties and functional advantages [17].

5.1 Synthetic Polymers

Synthetic polymers are widely employed in sustained release tablet formulations because of their reproducible performance, consistent quality, and well-defined physicochemical characteristics.

Hydroxypropyl methylcellulose (HPMC) is one of the most commonly used hydrophilic polymers in sustained release matrix tablets. Upon contact with gastrointestinal fluids, HPMC hydrates and forms a viscous gel layer around the tablet surface, which controls drug release primarily through diffusion and gradual matrix erosion. The viscosity grade and polymer concentration significantly influence the release profile, making HPMC a versatile choice for designing sustained release NSAID formulations used in RA management [4].

Ethyl cellulose is a hydrophobic, water-insoluble polymer frequently used to retard drug release by limiting water penetration into the matrix structure. It is often combined with hydrophilic polymers to achieve desired release kinetics and provides sustained drug delivery through diffusion-controlled mechanisms [18].

Polyvinyl acetate is another synthetic polymer utilized in sustained release systems due to its excellent film-forming ability and stability. It is commonly applied in both matrix and coating-based formulations to provide controlled drug release with minimal polymer degradation [15].

Methacrylic acid copolymers, commonly known as Eudragit polymers, are widely used in matrix and reservoir systems. Depending on their chemical composition, these polymers can provide either pH-dependent or pH-independent release behaviour, allowing formulation scientists to tailor sustained release profiles according to therapeutic requirements in RA therapy [19].

5.2 Natural Polymers

Natural polymers are gaining increasing attention in sustained release tablet development due to their biodegradability, biocompatibility, and low toxicity.

Polysaccharides such as xanthan gum and guar gum exhibit significant swelling in aqueous environments, forming gel matrices capable of controlling drug diffusion. Their viscosity and swelling characteristics make them suitable for hydrophilic matrix systems [12].

Chitosan, a cationic polymer derived from chitin, possesses excellent film-forming and bioadhesive properties. In sustained release formulations, it can enhance drug retention and modulate release behaviour.

Sodium alginate is also widely used in controlled release systems due to its swelling capacity and ionotropic gelation properties. In the presence of divalent cations, it forms gel structures that help regulate drug release [21].

Overall, the selection of polymers for sustained release tablets in RA depends on factors such as drug–polymer compatibility, swelling characteristics, mechanical strength, and the intended release mechanism, ensuring optimized therapeutic performance.

6. Mechanisms of Drug Release from Sustained Release Tablets

Sustained release (SR) tablets are designed to deliver drugs at a controlled rate over an extended period, allowing maintenance of therapeutic plasma concentrations, reduction in dosing frequency, and minimization of adverse effects. Understanding the underlying drug release mechanisms is essential for developing effective SR formulations, particularly in chronic conditions such as rheumatoid arthritis (RA), where consistent drug levels are required for long-term symptom control. Drug release from SR systems generally occurs through diffusion, erosion, swelling, or a combination of these mechanisms [17].

6.1 Diffusion-Controlled Release

Diffusion-controlled release is one of the most common mechanisms observed in hydrophobic matrix systems and certain coated formulations. In this process, the drug diffuses through water-filled pores, channels, or the polymer matrix itself after contact with gastrointestinal fluids [4]. The driving force for diffusion is the concentration gradient between the drug within the matrix and the surrounding environment. Hydrophobic polymers such as ethyl cellulose or non-ionic Eudragit RS/RL are frequently used in diffusion-controlled systems because they slow water penetration, thereby prolonging drug release. These systems are particularly suitable for drugs with moderate to high aqueous solubility, as they can provide relatively uniform or near zero-order release profiles beneficial for RA therapy [22].

6.2 Erosion-Controlled Release

Erosion-controlled release occurs when the polymer matrix gradually dissolves or erodes in gastrointestinal fluids, leading to the release of the embedded drug. This mechanism is commonly associated with hydrophilic polymer systems, where erosion of the swollen gel layer significantly contributes to overall drug release. Polymers such as hydroxypropyl methylcellulose (HPMC), xanthan gum, and guar gum may undergo either surface erosion or bulk erosion depending on their viscosity and formulation characteristics. Surface erosion allows the dosage form to maintain its shape while releasing drug progressively, whereas bulk erosion involves simultaneous water penetration and polymer degradation throughout the matrix [23]. Such controlled erosion helps sustain therapeutic drug levels by prolonging residence time within the gastrointestinal tract.

6.3 Swelling-Controlled Release

Swelling-controlled release is typically observed in hydrophilic matrix tablets containing water-absorbing polymers. Upon exposure to gastrointestinal fluids, these polymers absorb water and swell, forming a hydrated gel layer around the tablet core. Drug molecules subsequently diffuse through this gel barrier into the surrounding medium. Swelling not only regulates drug diffusion but also increases the diffusion path length and reduces the risk of dose dumping. This mechanism is particularly important for RA medications that require prolonged plasma concentrations with minimal peak–trough fluctuations [24].

6.4 Combination Mechanisms

In most practical sustained release formulations, drug release is governed by a combination of diffusion, erosion, and swelling processes. Hydrophilic matrices often rely on both diffusion and erosion mechanisms, whereas hydrophobic systems primarily exhibit diffusion-controlled behaviour. By adjusting factors such as polymer type, concentration, tablet geometry, and excipient composition, formulation scientists can tailor release profiles to meet specific therapeutic requirements. Combination mechanisms are frequently employed in sustained release tablets for RA to achieve prolonged analgesic and anti-inflammatory effects while minimizing gastrointestinal toxicity [25].

7. Evaluation of Sustained Release Tablets

Sustained release (SR) tablets are complex dosage forms that require comprehensive evaluation to ensure consistent drug release, adequate mechanical strength, and reliable therapeutic performance. For chronic conditions such as rheumatoid arthritis (RA), where long-term therapy is essential, SR tablets must maintain plasma drug concentrations within the therapeutic window while minimizing adverse effects. Evaluation of SR formulations is generally categorized into pre-compression studies, post-compression testing, and in vitro drug release analysis [24].

7.1 Pre-Compression Parameters

Pre-compression evaluation focuses on the properties of the powder blend prior to tablet compression. These parameters are important for achieving uniform tablet weight, consistent drug content, and predictable release behaviour [26].

Angle of Repose:

The angle of repose is used to assess powder flowability. It is determined by measuring the angle formed when the powder flows through a funnel and accumulates on a flat surface. Angles below 30° generally indicate good flow properties, whereas values above 40° suggest poor flow, which may result in weight variation and content non-uniformity during tablet manufacturing [27].

Bulk Density:

Bulk density is defined as the mass of powder divided by its untapped volume. It reflects particle packing characteristics and is influenced by factors such as particle size, shape, and moisture content. Bulk density is also used in the calculation of flow-related parameters such as Carr’s index and the Hausner ratio [28].

Tapped Density:

Tapped density is measured after mechanically tapping the powder until no further reduction in volume occurs. This parameter provides insight into powder compressibility and the ability of particles to rearrange under mechanical stress.

Carr’s Index (Compressibility Index):

Carr’s index evaluates powder compressibility and flow behaviour and is calculated using the following equation:

Carr’s Index (%) = (Tapped Density − Bulk Density) / Tapped Density × 100

Values below 15% indicate good flowability, values between 15–25% suggest fair flow, and values above 25% indicate poor flow properties, which may negatively affect compressibility and tablet uniformity [29].

7.2 Post-Compression Parameters

Following compression, SR tablets are evaluated to ensure mechanical stability, uniformity, and accurate drug content.

Tablet Hardness:

Hardness testing measures the mechanical strength of tablets and their ability to withstand handling, packaging, and transportation. Optimal hardness ensures sufficient mechanical integrity without adversely affecting dissolution or drug release behaviour [30].

Friability:

Friability testing evaluates the tendency of tablets to crumble or break under mechanical stress. Tablets are rotated in a friabilator, and percentage weight loss is calculated. Typically, acceptable friability values are below 1%, indicating adequate mechanical stability [31].

Weight Variation:

Individual tablets are weighed and compared with the average tablet weight to ensure dose uniformity. Consistent weight is particularly important for SR formulations to maintain controlled drug release.

Drug Content Uniformity:

Content uniformity testing ensures that each tablet contains the intended amount of active pharmaceutical ingredient. Multiple tablets are assayed, and the percentage deviation from the label claim is calculated. Uniform drug distribution is essential to maintain stable plasma concentrations over extended periods [6].

7.3 In Vitro Drug Release Studies

In vitro dissolution studies are conducted to evaluate the drug release profile from SR tablets, typically using USP dissolution apparatus I or II. Parameters such as dissolution medium, rotation speed, and temperature are selected based on the physicochemical properties of the drug and the intended absorption site. Samples are collected at predetermined time intervals, filtered, and analyzed using techniques such as UV-visible spectroscopy or HPLC [32].

Release kinetics are evaluated by fitting cumulative drug release data to mathematical models such as zero-order, first-order, Higuchi, or Korsmeyer–Peppas models to better understand the underlying release mechanisms. These studies are essential for confirming that SR formulations, including those containing drugs like ibuprofen or diclofenac, maintain sustained therapeutic levels while minimizing peak–trough fluctuations in RA therapy [33].

8. Kinetic Modeling of Drug Release

A key component of developing sustained release (SR) tablets is kinetic modeling of drug release. It enables formulation scientists to improve the dosage form's composition and structure, clarify underlying mechanisms, and quantitatively characterize the release behaviour [32]. Precise kinetic analysis guarantees that medications for long-term ailments like rheumatoid arthritis (RA) sustain therapeutic plasma concentrations while reducing peak-trough fluctuations [17].

8.1 Zero-Order Kinetics

Drug release at a steady rate, regardless of drug concentration in the dose form, is described by zero-order kinetics. It can be stated mathematically as:

Qt=Q0+k0t

where k₀ is the zero-order release rate constant, Q is the amount of drug released at time t, and Q₀ is the initial amount of medication. For SR pills, zero-order release is perfect since it minimizes side effects, lowers the frequency of dose, and maintains steady plasma levels [24]. Zero-order kinetics are frequently approximated by hydrophilic matrix tablets with high polymer concentrations or reservoir systems with regulated polymeric coatings [34].

8.2 First-Order Kinetics

Drug release proportionate to the residual drug concentration in the dose form is described by first-order kinetics. It is stated as:

logC=logC0?−2.303kt?

Water-soluble medications in porous or erodible hydrophilic matrices typically exhibit first-order kinetics. As the medication is used up, the release rate gradually drops. For RA medications with modest solubility that show concentration-dependent diffusion, this approach is especially pertinent [36].

8.3 Higuchi Model

Drug release from homogeneous matrices is described by the diffusion-based Higuchi model. It is assumed that the polymer matrix is non-eroding and non-swelling, and that drug diffusion takes place along a concentration gradient. The equation for Higuchi is:

Qt=kHt

where k_H is the Higuchi dissolving constant and Q_t is the cumulative drug release at time t. For SR NSAID tablets made in hydrophilic or hydrophobic matrices, the model is frequently utilized. It sheds light on whether drug release is primarily regulated by diffusion [35][11].

8.4 Korsmeyer–Peppas Model

When analyzing drug release from polymeric systems with complex mechanisms or many phenomena (diffusion, swelling, erosion), the Korsmeyer-Peppas model is a semi-empirical equation. The model can be written as:

MtM∞=ktn

Where Mt/M∞

is the fraction of drug released at time t

, k

is the release rate constant, and n

is the release exponent indicating mechanism type. For cylindrical tablets:

• n≤0.45

  

  : Fickian diffusion
• 0.45<n<0.89

  

  : Anomalous (non-Fickian) transport
• n=0.89

  

  : Case-II transport (erosion-controlled)

This model is highly relevant for RA SR tablets, which often exhibit combined diffusion-erosion mechanisms due to hydrophilic matrices such as HPMC, xanthan gum, or guar gum [9].

8.5 Significance in RA Sustained Release Formulations

The mechanism that primarily controls drug release can be identified with the aid of kinetic modeling. Comprehending the kinetics enables the adjustment of polymer type, concentration, tablet geometry, and coating thickness, guaranteeing patient compliance and a sustained therapeutic impact. These models’ direct formulation design for the treatment of chronic RA in order to prevent peak-related toxicity while preserving potent analgesic and anti-inflammatory effects [12].

9. Recent Advances in Sustained Release Tablet Technology

Over the past decade, sustained release (SR) tablet technology has advanced significantly due to progress in polymer science, drug delivery strategies, and pharmaceutical manufacturing techniques. These developments aim to improve drug release predictability, enhance patient adherence, and optimize therapeutic outcomes, particularly in chronic conditions such as rheumatoid arthritis (RA), where long-term administration of anti-inflammatory drugs is required [13]. Recent innovations include novel polymer blends, advanced manufacturing technologies, three-dimensional (3D) printing, and pH-independent release systems [4].

9.1 Novel Polymer Blends

Traditional SR formulations often rely on single polymers such as hydroxypropyl methylcellulose (HPMC) or ethyl cellulose to control drug release. However, single-polymer systems may exhibit limitations including inconsistent swelling behaviour, inadequate mechanical strength, or incomplete release profiles [36]. Polymer blending, which involves combining hydrophilic and hydrophobic polymers, has emerged as an effective approach to overcome these challenges by utilizing complementary material properties.

For example, combining HPMC with hydrophobic polymers like ethyl cellulose or Eudragit can balance swelling, diffusion, and erosion mechanisms, thereby enabling near zero-order release profiles for commonly used RA drugs such as diclofenac or ibuprofen. Incorporation of natural polymers such as xanthan gum or chitosan alongside synthetic polymers may further improve biocompatibility while maintaining structural stability [11].

9.2 Hot-Melt Extrusion Technology

Hot-melt extrusion (HME) is a modern solvent-free manufacturing technique increasingly applied in sustained release tablet development. In this process, drug substances are dispersed within molten polymer matrices and subsequently extruded to produce uniform controlled-release granules or tablets. HME enhances content uniformity and eliminates issues associated with solvent use while potentially improving drug solubility and bioavailability [37].

For poorly soluble drugs used in RA therapy, HME facilitates the formation of amorphous solid dispersions, which can enhance dissolution and enable prolonged drug release. Additionally, this technique allows precise adjustment of polymer composition and matrix architecture, supporting the development of customized release profiles for long-term treatment [38].

9.3 3D-Printed Sustained Release Tablets

Three-dimensional (3D) printing technology has introduced new possibilities in oral drug delivery by enabling the fabrication of complex and patient-specific tablet designs. In RA therapy, 3D-printed SR tablets allow precise control over tablet geometry, internal channels, and multi-layered structures, which directly influence drug release kinetics [39].

Techniques such as fused deposition modeling (FDM) and semi-solid extrusion enable the production of multi-drug or multi-release systems combining immediate and sustained release layers within a single dosage form. These innovations may reduce pill burden and allow personalized dosing based on individual pharmacokinetics or disease severity, ultimately improving patient compliance [40].

9.4 pH-Independent Release Systems

Conventional SR tablets may exhibit variable release profiles due to pH-dependent polymer behaviour across different regions of the gastrointestinal tract. Recent research focuses on developing pH-independent matrix and coating systems capable of maintaining consistent drug release irrespective of environmental pH. Polymer combinations such as HPMC with ethyl cellulose or Eudragit RS/RL blends provide more stable swelling and diffusion characteristics, ensuring reliable therapeutic outcomes for orally administered RA medications [41].

9.5 Implications for RA Therapy

These technological advances have significantly improved the design and clinical potential of sustained release tablets for RA management. Novel polymer blends and manufacturing technologies such as HME enable controlled and reproducible drug release, reducing peak–trough fluctuations and minimizing gastrointestinal side effects commonly associated with NSAIDs. Meanwhile, 3D printing introduces opportunities for personalized therapy tailored to patient-specific needs. Collectively, these innovations support the development of next-generation SR formulations that enhance safety, efficacy, and patient adherence in chronic RA treatment [11][40].

10. Challenges in Sustained Release Tablet Formulation

Sustained release (SR) tablets provide several advantages in the management of chronic diseases such as rheumatoid arthritis (RA), including prolonged therapeutic action, reduced dosing frequency, and improved patient adherence. However, despite these benefits, the formulation of SR tablets presents multiple challenges that can influence product performance, safety, and manufacturing feasibility. Addressing these issues requires a comprehensive understanding of drug physicochemical properties, appropriate polymer selection, optimized manufacturing processes, and reliable in vitro–in vivo correlations [24].

10.1 Dose Dumping Risk

One of the major concerns associated with SR formulations is dose dumping, a situation in which the drug is released rapidly instead of gradually over time. This phenomenon may occur due to polymer degradation, formulation defects, inadequate coating, or unexpected interactions with gastrointestinal fluids. The risk becomes particularly significant for NSAIDs used in RA therapy, as sudden increases in plasma drug levels may lead to gastrointestinal irritation, renal complications, or cardiovascular risks [42]. Factors such as matrix porosity, polymer swelling characteristics, and mechanical stress during processing or handling can influence dose dumping. To minimize this risk, formulators focus on optimizing polymer composition, improving matrix integrity, and employing robust coating techniques alongside appropriate compression parameters [43].

10.2 Variability in Gastrointestinal Transit Time

Gastrointestinal (GI) transit time plays a crucial role in determining the release and absorption of orally administered SR tablets. Physiological variations among patients, including differences in intestinal motility, gastric emptying rate, and pH conditions, may result in variability in drug release and plasma concentration profiles [44]. For example, delayed gastric emptying or concurrent administration of other medications in RA patients may lead to incomplete or altered drug release. To address these challenges, formulation strategies such as gastro-retentive systems, pH-independent polymer matrices, and multiparticulate delivery systems are commonly employed to maintain consistent release despite physiological variability [11].

10.3 Polymer–Drug Incompatibility

Polymer–drug incompatibility is another important challenge during SR formulation development. Chemical or physical interactions between the drug and polymer can cause reduced stability, altered release behavior, degradation, or changes in tablet mechanical properties. For instance, acidic drugs like diclofenac may interact with certain basic polymers, potentially affecting release kinetics and stability. Therefore, compatibility studies using analytical techniques such as Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and X-ray Diffraction (XRD) are essential to ensure appropriate polymer selection and formulation stability [9].

10.4 Scale-Up Difficulties

Transitioning from laboratory-scale development to industrial manufacturing often introduces scale-up challenges. Variations in mixing efficiency, compression force, drying conditions, or granule flow properties may result in inconsistent drug content, altered release profiles, or compromised tablet integrity. Careful process optimization, implementation of stringent quality control measures, and adherence to Good Manufacturing Practices (GMP) are necessary to maintain reproducibility and meet regulatory requirements during large-scale production [45].

10.5 Strategies to Overcome Challenges

Overcoming these formulation challenges requires a holistic and systematic approach. Key strategies include selecting robust polymer systems, particularly hydrophilic–hydrophobic blends or pH-independent polymers, performing thorough pre- and post-compression evaluations to ensure adequate mechanical strength and content uniformity, and establishing reliable in vitro–in vivo correlations (IVIVC) to predict drug release under physiological conditions. Additionally, advanced manufacturing techniques such as hot-melt extrusion and 3D printing may enhance reproducibility while reducing the risk of dose dumping [46]. Collectively, these approaches contribute to the development of safe, effective, and patient-friendly sustained release formulations for RA therapy.

11. Future Prospects of Sustained Release Tablets in Rheumatoid Arthritis

Rheumatoid arthritis (RA) requires long-term pharmacological management to control inflammation, relieve pain, and prevent progressive joint damage. Sustained release (SR) tablets play an important role in maintaining stable therapeutic drug levels while reducing dosing frequency and improving patient adherence. Despite these advantages, conventional SR formulations still face certain limitations, including the risk of dose dumping, variability in gastrointestinal transit, and limited flexibility for individualized therapy. Current research is therefore focused on developing advanced SR systems that address these challenges while improving treatment safety and overall therapeutic outcomes [24].

11.1 Smart Polymers for Controlled and Responsive Release

Smart polymers, also known as stimuli-responsive polymers, are gaining attention in the development of advanced SR formulations. These materials are capable of responding to specific physiological triggers such as pH, temperature, or enzymatic activity, enabling more precise and controlled drug release. In RA therapy, such systems may be designed to release anti-inflammatory drugs in response to inflammatory signals or circadian variations in disease activity [47]. For example, pH-sensitive polymers can protect the drug from the acidic gastric environment and promote release in the intestinal region, thereby minimizing gastrointestinal irritation. Similarly, enzyme-responsive systems may allow selective drug release at inflamed sites, potentially improving therapeutic efficacy while reducing systemic exposure.

11.2 Personalized Dosage Forms via 3D Printing

Personalized medicine is becoming increasingly important in RA management due to variations in disease severity, pharmacokinetics, and individual patient response. Three-dimensional (3D) printing technologies, including fused deposition modeling (FDM) and semi-solid extrusion, offer the possibility of manufacturing SR tablets with customized shapes, doses, and release profiles [39]. Multi-layered or compartmentalized tablets can combine immediate-release and sustained-release components within a single dosage form, supporting chronotherapeutic approaches that align drug release with symptom patterns. Such innovations may reduce pill burden and enhance adherence, particularly in patients requiring complex treatment regimens [40].

11.3 Combination Therapy Sustained Release Tablets

Combination therapy is commonly employed in RA treatment, often involving NSAIDs, corticosteroids, or disease-modifying antirheumatic drugs (DMARDs). Future SR formulations are expected to focus on co-delivery systems capable of incorporating multiple drugs with different release characteristics into a single tablet. Multi-layer matrices or multiparticulate systems can allow sequential or simultaneous drug release, thereby simplifying therapy and improving compliance. Additionally, combination SR systems may enhance therapeutic synergy, allowing lower individual doses and potentially reducing adverse effects [49].

11.4 Integration with Digital and Monitoring Technologies

Another emerging direction in SR tablet development involves integration with digital health technologies. Concepts such as ingestible sensors or smart monitoring platforms could enable real-time tracking of drug release, gastrointestinal transit, or patient adherence. The data generated may support clinicians in making timely adjustments to therapy, thereby improving long-term disease management in RA patients. The combination of SR drug delivery systems with digital monitoring tools represents a promising step toward more precise and patient-centered treatment approaches [50].

CONCLUSION

Sustained release (SR) tablets have emerged as an important oral drug delivery strategy for the long-term management of rheumatoid arthritis (RA), a chronic autoimmune disorder that requires continuous pharmacological intervention. By enabling controlled and prolonged drug release, SR formulations help maintain relatively stable plasma drug concentrations, reduce peak–trough fluctuations, and decrease dosing frequency, which collectively improves patient adherence and overall treatment outcomes. Advances in polymer science, including the use of hydrophilic, hydrophobic, and stimuli-responsive polymers, have supported the development of robust matrix and reservoir systems capable of achieving predictable release profiles.

In addition, modern manufacturing technologies such as hot-melt extrusion, polymer blending, and three-dimensional (3D) printing have expanded the possibilities for designing flexible and reproducible SR formulations. These approaches allow the development of personalized dosage forms, combination therapies, and tailored release characteristics suited to individual patient needs. Despite these advancements, certain challenges remain, including the risk of dose dumping, polymer–drug incompatibility, and variability associated with physiological conditions. Comprehensive evaluation methods and kinetic modeling play a crucial role in ensuring consistent performance and clinical reliability.

Looking ahead, future research is expected to focus on smart polymer systems, chronotherapeutic designs, and integration with digital monitoring technologies, which may transform SR tablets into more responsive and patient-centered therapeutic platforms. Overall, sustained release tablets represent a sophisticated and effective approach for RA management, with continued innovation likely to further enhance long-term adherence, safety, and therapeutic efficacy.

REFERENCES

1. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–196.
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
3. Chien YW. Oral drug delivery systems. In: Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker; 1992. p. 139–196.
4. Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery. Pharm Sci Technol Today. 2000;3(6):198–204.
5. Hoffman A. Pharmacodynamic aspects of sustained release preparations. Adv Drug Deliv Rev. 2008;60(9):1117–1126.
6. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers; 2019.
7. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection. N Engl J Med. 2008;354(6):657–659.
8. Qiu Y, Zhang GZ. Design and evaluation of sustained release oral dosage forms. Adv Drug Deliv Rev. 2017;117:1–10.
9. Reddy KR, Mutalik S. Sustained release matrix tablets: formulation and evaluation. Int J Pharm Sci Rev Res. 2012;12(1):1–10.
10. Reddy KR, Short MD, Basit AW. An in vivo comparison of intestinal pH and bacteria. J Pharm Sci. 2008;97(12):1–11.
11. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–223.
12. Jain NK. Controlled and Novel Drug Delivery. New Delhi: CBS Publishers; 2016.
13. Siepmann J, Peppas NA. Hydrophilic matrices for controlled drug delivery: An improved mathematical model. Int J Pharm. 2001;218(1–2):139–150.
14. Reza MS, Quadir MA, Haider SS. Development of theophylline sustained release dosage form based on hydrophobic matrix system. Drug Dev Ind Pharm. 2003;29(4):339–347.
15. Felton LA. Mechanisms of polymeric film formation. Int J Pharm. 2013;457(2):423–427.
16. Basit AW, Podczeck F, Newton JM, Waddington WA, Ell PJ. The influence of formulation on gastrointestinal transit. J Control Release. 2004;99(1):3–14.
17. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose. Adv Drug Deliv Rev. 2012;64:163–174.
18. Reza MS, Quadir MA, Haider SS. Development of sustained release dosage forms using ethyl cellulose. Drug Dev Ind Pharm. 2003;29(4):339–347.
19. Evonik Industries. Eudragit® Polymers for Controlled Drug Delivery. Darmstadt: Evonik; 2019.
20. Dash M, Chiellini F, Ottenbrite RM, Chiellini E. Chitosan—A versatile semi-synthetic polymer in drug delivery. Prog Polym Sci. 2011;36(8):981–1014.
21. George M, Abraham TE. Polyionic hydrocolloids for controlled release formulations. J Control Release. 2006;114(1):1–14
22. Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of formulation variables on drug release from HPMC matrix tablets. J Control Release. 2003;86(1):75–89.
23. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63(3):235–259.
24. Aulton ME, Taylor K. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.
25. Li X, Lee BJ, Jung J. Mechanistic modeling of drug release from combined diffusion-erosion matrix tablets. Int J Pharm. 2016;500:109–119.
26. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 4th ed. Mumbai: CBS Publishers; 2013.
27. Shah K, Patel S, Raval M. Preformulation studies and powder characterization in pharmaceutical dosage form development. Int J Pharm Sci Rev Res. 2012;17(1):11–18.
28. Banker GS, Anderson NR. Tablet and Capsule Dosage Forms: Pharmaceutical Dosage Forms: Tablets. Vol. 1. Marcel Dekker; 1987.
29. Karmarkar AP, et al. Evaluation of powder flow properties for sustained release formulations. Int J Pharm Pharm Sci. 2011;3(3):45–50.
30. Gennaro AR. Remington: The Science and Practice of Pharmacy. 21st ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
31. Indian Pharmacopoeia. The Indian Pharmacopoeia. Vol. II. Ghaziabad: Indian Pharmacopoeia Commission; 2018.
32. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–133.
33. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52(12):1145–1149.
34. Higuchi T. Mechanism of sustained-action medication. J Pharm Sci. 1963;52(12):1145–1149.
35. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.
36. Li S, Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of polymer blends on drug release from hydrophilic matrices. J Control Release. 2003;86(1):75–89.
37. Repka MA, et al. Pharmaceutical applications of hot-melt extrusion: Part I. Drug Dev Ind Pharm. 2007;33(9):909–926.
38. Maniruzzaman M, et al. Hot-melt extrusion of drugs for sustained release. Pharm Dev Technol. 2012;17(6):657–672.
39. Goyanes A, et al. 3D printing of medicines: Engineering personalized drug release. Int J Pharm. 2015;494(2):568–577.
40. Khaled SA, et al. 3D printed sustained release tablets for chronic disease therapy. Int J Pharm. 2015;494(2):643–650.
41. Bodmeier R, McGinity JW. The development of pH-independent sustained release coatings. Drug Dev Ind Pharm. 1988;14(2):241–257.
42. Bodmeier R, McGinity JW. Pharmaceutical aspects of dose dumping in sustained release tablets. Drug Dev Ind Pharm. 1988;14(2):241–257.
43. Jain S, et al. Prevention of dose dumping in matrix-based controlled release systems. Int J Pharm. 2014;464:37–48.
44. Patel VR, et al. Gastrointestinal variability and its impact on oral controlled release systems. Drug Dev Ind Pharm. 2006;32(5):541–554.
45. Repka MA, et al. Scale-up challenges in sustained release tablet manufacturing. Drug Dev Ind Pharm. 2007;33(9):909–926.
46. Maniruzzaman M, et al. Advanced techniques in sustained release tablet production: Hot-melt extrusion and 3D printing. Pharm Dev Technol. 2012;17(6):657–672.
47. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev. 2001;53(3):321–339.
48. Khaled SA, et al. 3D-printed sustained release tablets for chronic disease therapy. Int J Pharm. 2015;494(2):643–650.
49. Patel VR, et al. Multi-drug delivery systems in chronic disease management. Drug Dev Ind Pharm. 2006;32(5):541–554.
50. Prasad LK, Smyth H. 3D printing technologies for drug delivery applications: Current progress and future prospects. Drug Dev Ind Pharm. 2016;42(7):1019–1030.